Skip to main content

MFG acquires testing firm

US custom manufacturing firm MFG Chemical has acquired Masters Company from private ownership. Terms were not disclosed and the deal has already been completed. Masters is based in Chicago and is active in the water treatment market, mainly in North America, though it has some international customers. It supplies reagents and test kits, carries out custom blending and manufacturing, makes private label products and offers analytical services for industrial water treatment.

Progress being made in non-animal testing: ECHA

ECHA has published its fifth triennial report on the use of alternatives to testing on animals for REACH. Based on data from 12,439 registered substances up until 31 July 2022, it concluded that progress is being made and alternatives are widely used when assessing the safety of chemical substances.

Changes to REACH requirements

The European Commission has revised certain information requirements for registering chemicals under REACH. It advised companies to start preparing as the changes will start to apply in October. Further advice will be issued in 2H and changes will be made accordingly in Iuclid.

The main changes concern requirements and specific rules for the adaptation of:

* In vitro and in vivo studies, when further studies are needed based on mutagenicity concerns

New owner for Envigo

Inotiv, a US CRO specialising in nonclinical and analytical drug discovery and development services, has reached an agreement to acquire research models and services Envigo. The cash and shares deal gives UK-headquartered Envigo an enterprise value of about $545 million, and the combined company one of around $1.2 billion.

First non-animal allergy testing strategy approved

The Organisation for Economic Co-operation & Development (OECD) has approved the world’s first toxicology testing strategy without animal testing. This can now be used to test for skin sensitisation and any products that pass can be placed on the market.

The strategy, which consists of three ‘alternative’ methods, was jointly developed and validated over ten years by BASF and Givaudan, in partnership with various companies and scientific institutions, notably IIVS. It is claimed to have better predictivity for human allergy risks than traditional animal testing.

Subscribe to testing